Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-based neoadjuvant and adjuvant therapy in HER2-expressing ovarian cancer
ChiCTR2600117491Phase 4Not yet recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Jan 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of disitamab vedotin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Liaoning Province Cancer Hospital. Primary endpoint: Completed resection rate (CRR). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2600117491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117491.